352672-60-7

Basic information

• Product Name: 5-bromo-N³-(phenylmethylene)pyridine-2,3-diamine
• Synonyms: 5-bromo-N³-(phenylmethylene)pyridine-2,3-diamine
• CAS NO: 352672-60-7
• Molecular Weight: 276.135
• Mol File: 352672-60-7.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 5-bromo-N³-(phenylmethylene)pyridine-2,3-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-N³-(phenylmethylene)pyridine-2,3-diamine(352672-60-7)
• EPA Substance Registry System: 5-bromo-N³-(phenylmethylene)pyridine-2,3-diamine(352672-60-7)

Safety Data

• Hazardous Substances Data: 352672-60-7(Hazardous Substances Data)

Upstream product

• 38875-53-5 5-bromo-pyridine-2,3-diamine 
• 100-52-7 benzaldehyde 

Downstream Products

• 65147-89-9 6-bromo-2-phenyl-1H-imidazo<4,5-b>pyridine 

Relevant articles and documents

SOLID FORMS OF A BET INHIBITOR

The present disclosure relates to a mesylate salt/co-crystal of a BET bromodomain inhibitor, l-benzyl-6-(3,5-dimethylisoxazol-4-yl)-N-methyl-lH-imidazo[4,5-b]pyridine-2-amine, that modulates or inhibits the activity of BET bromodomain-containing proteins, pharmaceutical compositions, therapeutic uses, and processes for making a mesylate salt/co-crystal of said BET bromodomain inhibitor. These inhibitors have the potential to cure, treat, or improve the lives of subjects suffering from diseases such as cancer, inflammatory and cardiovascular diseases.

COMBINATION THERAPY FOR THE TREATMENT OF PROSTATE CANCER

The invention provides methods for treating prostate cancer, including metastatic castration-resistant prostate cancer, comprising administering to a subject in need thereof a BET faromadomain inhibitor in combination with a second agent.

COMBINATION THERAPY FOR THE TREATMENT OF ESTROGEN-RECEPTOR POSITIVE BREAST CANCER

Methods for treating estrogen receptor positive (ER+) breast cancer, comprising administering to a subject in need thereof, a BET bromodomain inhibitor in combination with a second agent, selected from a selective-estrogen receptor degrader (SERD), a selective-estrogen receptor modulator (SERM) and a selective CDK4/6 inhibitor. The BET bromodomain inhibitor is selected from 1-benzyl-6-(3, 5-dimethylisoxazol-4-yl)- N-methyl-1H-imidazo[4,5-b]pyridin-2-amine (Compound I), 1-benzyl-6-(3,5- dimethylisoxazol-4-yl)-1H-imidazo[4,5-b]pyridin -2-amine, and pharmaceutically acceptable salts/co-crystals thereof.